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RIG-IHemorrhagic fever viruses are associated with rapidly progressing severe disease with high case fatality,
making them of public health and biothreat importance. Effective antivirals are not available for most of the
members of this diverse group of viruses. A broad spectrum strategy for antiviral development would be very
advantageous. Perhaps the most challenging target would be the highly immunosuppressive ﬁloviruses,
ebolavirus and marburgvirus, associated with aerosol infectivity and case fatalities in the 80–90% range.
Here we report that activation of evolutionarily conserved cytosolic viral nucleic acid sensor, RIG-I can cause
severe inhibition of ebolavirus replication. These ﬁndings indicate that RIG-I-based therapies may provide an
attractive approach for antivirals against Ebola hemorrhagic fever, and possibly other HF viruses.Published by Elsevier Inc.IntroductionThe genus Ebolavirus contains ﬁve virus species; Zaire, Sudan, Cote
d'Ivoire, Reston, and Bundibugyo ebolavirus (Sanchez et al., 2007;
Towner et al., 2008). These viruses have been identiﬁed in various
regions of sub-Saharan Africa and the Philippines, and are classiﬁed as
biosafety level 4 (BSL-4) pathogens and select agents based on their
association with high case fatality, human-to-human transmission.
The high genetic and antigenic diversity of these viruses coupled with
the sporadic nature of the disease outbreaks pose considerable
challenges for the development of effective preventive vaccines and
antiviral therapies.
Normally, cell recognition of pathogen-associated molecular
patterns leads to activation of an innate and adaptive immune
responses which contribute to blocking virus replication and spread
(Bowie and Unterholzner, 2008; Takeuchi and Akira, 2009). However,
profound immunosuppression and high virus titers, reaching 109 pfu/
ml in some cases, are hallmarks of fatal Ebola hemorrhagic fever cases
(Sanchez et al., 2004; Towner et al., 2004). While some negative sense
RNAviruses avoid activation of innate immune responses bymodifying
their RNA 5′ ends during virus transcription (Habjan et al., 2008),
ebolavirus uses alternate mechanisms involving the virus VP24 and
VP35proteins. VP24has been shown to interferewith the IFN signaling
pathwaybyblocking the translocation of the phosphorylated STAT-1 tose of the authors and do not
ontrol and Prevention.
Inc.the nucleus (Reid et al., 2006). VP35 has been shown to be involved in
the block of many different steps of the host immune response. These
include directly inhibiting RIG-I function (Cárdenas et al., 2006), IRF-3
phosphorylation, dimerization and nuclear translocation (Basler et al.,
2003), and impairment of the function of IKKe and TBK-1 kinases
(Prins et al., 2009). In addition, VP35 has been shown to block PKR
activation (Feng et al., 2007) and suppression of RNA silencing
(Haasnoot et al., 2007). These observations suggest that an interven-
tion which tips the initial balance between host innate immune
response versus virus replication and suppression of innate immunity
might serve as an effective antiviral strategy.
Earlier studies have demonstrated that recognition of viral RNA by
cytoplasmic pathogen sensors such as Retinoic Acid Inducible Gene-I
(RIG-I) is critical in the activation of the type I interferon-dependant
antiviral innate immune response. RIG-I consists of two N-terminal
CARD domains and a C-terminal helicase domain. Functional analysis
has revealed that theN-terminal CARDdomains are sufﬁcient to induce
type I interferon induction (Yoneyama et al., 2004). Furthermore, 5′
PPP-ssRNA (Hornung et al., 2006; Pichlmair et al., 2006; Saito et al.,
2008), or dsRNA (Takahasi et al., 2008) are known to serve as ligands
that activate RIG-I. Here we tested the hypothesis that stimulation of
host cell innate immune responses by 5'PPP-RNA dependent RIG-I
activation or by expression of constitutively active N-terminal domain
of RIG-I, may be an effective antiviral strategy for ebolavirus.
Results and discussion
A 19mer 5'PPP-RNA which had previously been shown to be a
particularly potent inducer of RIG-I, was produced by T7 RNA
Fig. 1. RIG-I activation upregulated IFNβ and RIG-I mRNA expression. A549 cells were transfected for 24 h with 5′PPP-RNA, CIAP-RNA, pNT-RIG-I or control vector or infected for 24 h
with Ad-N-RIG-I or control Ad-GFP at an MOI of 300 for 24 h. The cells were then infected with ebolavirus at an MOI of 0.5 for 48 h, total cellular RNA was extracted from each
experimental group and real time PCR reactions were conducted. The RIG-I primers were designed to detect endogenously induced RIG-I and would not detect the transiently
expressed N-terminal RIG-I by pNT-RIG-I plasmid or Ad-N-RIG-I infection. The threshold cycle number for cDNAwas normalized to that of β-actin mRNA, and the resulting value was
converted to a linear scale. For RT-PCR analysis, data from three independent experiments from RNA isolated from duplicate cultures were tested in duplicate. All data points fell into
a normal distribution and there were no outliers.
Fig. 2. Sustained induction of RIG-I in Zaire ebolavirus infected cells. A549 cells in
duplicate cultures for each treatment were transfected for 24 h with 5′PPP-RNA, CIAP-
RNA, pNT-RIG-I or vector alone or infected for 24 hwith Ad-N-RIG-I or control Ad-GFP at
an MOI of 300 for 24 h. The cells were then infected with ebolavirus at an MOI of 0.5 for
48 h and lysed. Equal quantities of solubilized protein were resolved in SDS-PAGE gel,
transferred to nitrocellulose membrane and probed with anti-RIG-I rabbit polyclonal
antibody. As a loading control the same membrane was stripped and probed with anti-
β-actin antibody.
12 Rapid Communicationpolymerase in vitro synthesis as described previously (Hornung et al.,
2005; Kim et al., 2004). In addition, we over-expressed the N-terminal
CARD domain of RIG-I using either a plasmid construct (pNT-RIG-I) or
a recombinant Adenoviral vector (Ad-N-RIG-I). The construction of
the pNT-RIG-I has been described previously (Yoneyama et al., 2004).
For the construction of Ad-N-RIG-I, cDNA encoding EGFP and N-RIG-I
under separated CMV promoters was inserted in non-replicating
human Adenovirus serotype 5 vector. The replication deﬁcient
Ad-N-RIG-I was included in this study for its high efﬁciency RIG-I
gene delivery and its possible future use in in vivo experiments.
Lung ﬁbroblast (A549) cells were chosen for the study, based on
their known high susceptibility to ebolavirus infection, ease of
transfection, and robust innate immune responses. The cells were
transfected with 5′PPP-RNA, plasmid expressed N-terminal RIG-I
(pNT-RIG-I), or infected with Ad-N-RIG-I at an moi of 300, 24 h prior
to infection with Zaire ebolavirus at an moi of 0.5. RNA which had
been calf intestinal alkaline phosphatase (CIAP) treated to remove
the 5′PPP, or vector alone, or control Ad vector lacking the N-terminal
RIG-I ORF (Ad-GFP) were used as controls. At 48 h post ebolavirus
infection, cell supernatants were collected and cell monolayers were
lysed with either RNA extraction buffer (Tripure) or protein lysis
buffer.
The expression of RIG-I and IFN-β mRNAs were examined by real
time RT-PCR (Fig. 1). Cells transfected with 5′PPP-RNA showed a 100-
fold increase in IFN-β mRNA and an approx. 10-fold increase in RIG-I
mRNA. This induction was speciﬁc to 5′PPP-RNA as mock-transfected
or cells transfected with RNA lacking the 5′PPP showed no induction.
Ebolavirus infection alone did not induce RIG-I in either mock-
transfected cells or cells transfected with RNA lacking the 5′PPP
(Fig. 1). Cells transfected with pNT-RIG-I exhibited a 20-fold increase
in IFN-β mRNA and a 15-fold increase in RIG-I mRNA. The induction
was speciﬁc to pNT-RIG-I as mock-transfected cells, or cells trans-
fected with vector alone, showed no induction. Similarly, infection of
cells with Ad-N-RIG-I resulted in a 60-fold increase for IFN-β mRNA
and a 15-fold increase on RIG-I mRNA over the Ad-GFP control. These
results demonstrate that even in the presence of highly immunosup-
pressive ebolavirus infection RIG-I mediated innate immune responses
can be stimulated with 5′PPP-RNA or by over-expression of RIG-I.Similar results were seen at the protein level. For instance,
stimulation of RIG-I protein expression was observed in cells
transfected with 5'PPP-RNA (lanes 2 and 5), or plasmid (pNT-RIG-I)
(lane 8) or Adeno vector (Ad-N-RIG-I) (lane 11) over-expressing the
N-terminal domain of RIG-I (Fig. 2). Ebolavirus infection slightly
reduced the level of RIG-I in comparison to uninfected cells (compare
lanes 5 and 2).
Induction of the RIG-I has been shown previously to reduce viral
replication for other negative strand RNA viruses such us vesicular
stomatitis and inﬂuenza viruses (Kato et al., 2006; Kumar et al., 2006).
To examine whether the increased RIG-I induction observed in the
treated cells infected with Zaire ebolavirus resulted in inhibition of
virus replication, we measured virus protein expression levels in the
cell lysates (Fig. 3A) and quantitated virus release in the cell (Fig. 3B).
Using an antibody speciﬁc for Zaire ebolavirus VP35, a striking
reduction in virus protein expression (relative to mock treated cells)
was observed in the 5′PPP-RNA transfected cells (lane 2), and in the
Fig. 3. RIG-I activation inhibited ebolavirus protein expression, and virus release. A549 cells were processed as described in Fig. 1. At 48 h post infection supernatants were collected
and the cells were treated with protein lysis buffer. Total protein lysates were analyzed by SDS-PAGE followed by transfer to nitrocellulose membrane. Ebolavirus VP35 protein was
detected using a VP35 speciﬁc monoclonal antibody (aVP35-1). As a loading control, the same membrane was stripped and probed with anti-β-actin antibody (Panel A). The
collected supernatants were analyzed for ebolavirus replication (Panel B).
13Rapid CommunicationRIG-I over-expressing cells transfected with pNT-RIG-I (lane 5) or
infected with Ad-N-RIG-I (lane 8). More signiﬁcantly, we demon-
strated a more than 1000-fold inhibition of infectious virus yield from
infected cells treated with the 5′PPP-RNA (Fig. 3B). Similarly, over-
expression of the N-terminal RIG-I by plasmid transfection or
Adenovirus vector infection resulted in a more than 500-fold decrease
of ebolavirus titers compared to the mock infected cells. It was noted
that a modest (10-fold) decrease in ebolavirus replication was also
seen in the control Ad-GFP (lacking the RIG-I ORF) infected cells
relative to the mock treated cells. The reason for this is unclear, but
appears unrelated to the more potent levels of RIG-I mediated virus
inhibition.
There are currently no licensed vaccines and no effective antiviral
drugs available for ebolaviruses. Several antiviral approaches are
currently being investigated with variable success, including protein
cleavage inhibitors (Ströher et al., 2007), antisense RNAs, and siRNAs
(Spurgers et al., 2008; Warﬁeld et al., 2006). Of these, the ebolavirus
antisense phosphorodiamidate morpholino oligomers appear the
most promising (Warﬁeld et al., 2006). However, the cumulative
data so far suggest that it is likely that a combination of different drugs
may be necessary for effective treatment or to achieve short-term
protection (Paragas and Geisbert, 2006).We show here that activation
of RIG-I can very effectively suppress ebolavirus replication and shows
considerable promise for use against these important public health
and bioterrorism threats.
Previous studies of ebolavirus infected patients demonstrated that
cases going on to survive infection had at approx. 2–3 log lower
viremias at early times post onset of disease relative to cases going on
to fatal outcome (Sanchez et al., 2004; Towner et al., 2004). Interferon
treatment alone has shown only a 10- to 100-fold reduction of ebo-
lavirus replication in cell culture (Jahrling et al., 1999). Our ﬁndings
that 5′PPP-RNA treatment could reduce ebolavirus replication by 3
logs, suggests that these high levels of virus inhibition may be
sufﬁcient to impact disease outcome. This study suggests that
developing small molecules that activate RIG-I may have therapeutic
potential for the treatment of ebolavirus infected individuals or for
prophylactic use to ensure short-term protection of disease outbreak
response personnel and laboratory workers. Recent advances in thedelivery of small RNA molecules (Castanotto and Rossi, 2009) suggest
this approach is sufﬁciently promising to consider testing in animal
models. Alternatively the replication deﬁcient Adenovirus vectors
expressing N-terminal RIG-I remains another viable approach on the
path of developing short-term prophylactics for highly pathogenic HF
viruses such as Zaire ebolavirus.
Materials and methods
Cells and viruses
Vero E6 and A549 cells were maintained in Dulbecco's modiﬁed
Eagle's medium (DMEM) containing 100 U/ml penicillin, 100 U/ml
streptomycin, and 10 mM HEPES buffer (complete) supplemented
with 10% fetal bovine serum (FBS). The Zaire ebolavirusMayinga strain
stock preparation and virus titration were performed in Vero E6 cells.
All work with infectious ebolavirus was performed in the biosafety
level 4 laboratory at the Centers for Disease Control and Prevention.
Samples were inactivated with 2×106 to 5×106 rd from a Gammacell
irradiator when necessary. Production and quantiﬁcation of type-5
adenoviral vectors expressing either EGFP under the control of CMV
promoter or expressing both EGFP and FLAG-tagged human N-
terminal RIG-I under the control of separate CMV promoter was
carried out by Vector BioLabs, Inc.
In vitro synthesis of 5′PPP-RNA
In vitro transcribed RNAs were synthesized using T7 RNA
polymerase. Using annealed complimentary oligo nucleotides, a
DNA template was constructed that contains a T7 RNA polymerase
promoter followed by the sequence of interest (AGCUUAACCUGUC-
CUUCAA) to be transcribed (Yoneyama et al., 2004). 20 pmol of the
DNA template were incubated with 25 U T7 RNA polymerase, 40 U
RNase inhibitor in a buffer containing 40mMTris–Hcl (pH 8.0),10mM
DTT, 2 mM spermidine–HCl, 20 mM MgCl2 and NTPs. DNA template
was digested with DNase I and RNA was puriﬁed using phenol:
chloroform extraction and ethanol precipitation. Size and integrity of
RNA was analyzed by gel electrophoresis. Calf intestine alkaline
14 Rapid Communicationphosphatase (CIAP) treatment was performed to remove tri-phos-
phate groups from in vitro synthesized RNA. Brieﬂy, 100 μg of in vitro
transcribed RNA was treated with 150 U of CIAP for 3 h at 37 °C in a
buffer containing 50 mM Tris–HCl (pH 8.0), 0.1 mM EDTA and 50 U of
RNase inhibitor. RNA was puriﬁed as described above.
Viral infection and real time RT-PCR
To assess 5′PPP-RNA induced RIG-I and IFNβ expression A549 cells
(1×106 cells/well) in a 6-well tissue culture plate in duplicate
cultures for each treatment were mock-transfected (control) or
transfected with pEF-BOS (4 μg) or pEF-BOS-NT-RIG-I (4 μg), or 5′
PPP-RNA (2 μg), CIAP-RNA (2 μg) using lipofectamine 2000 or infected
with either Adenoviral vector expression GFP or GFP and N-RIG-I at an
MOI of 300:1 for 24 h. A549 cells were then infected with ebolavirus at
an MOI of 0.5 for 48 h. Cells were then harvested and total RNA was
extracted from each experimental group using Tri-Pure reagent. Real
time PCR reactions were conducted, using 2 μg total cellular RNA and
Superscript III One-Step RT-PCR (Invitrogen) according to the
manufacturer's instructions. Real time PCR was performed with
denaturation at 94 °C for 15 s, annealing at 56 °C for 30 s, and
extension at 72°C for 30 s for a total of 45 cycles. Two sets of PCR assays
were performed for each sample using the following primers speciﬁc
for cDNA of each of the following genes.
IFNβ: forward 5′-TGG GAG GCT TGA ATA CTG CCT CAA-3′
reverse 5′-TCT CAT AGA TGG TCA ATG CGG CGT-3′
RIG-I: forward 5′-AAA CCA GAG GCA GAG GAA GAG CAA-3′
reverse 5′-TCG TCC CAT GTC TGA AGG CGT AAA-3′
β-actin: forward 5′-ACC AAC TGG GAC GAC ATG GAG AAA-3′
reverse 5′-TAG CAC AGC CTG GAT AGC AAC GTA-3′
The RIG-I primer set used was designed to amplify only the C-
terminal domain of RIG-I (nt position 2335 to 2476). This is present in
the endogenous RIG-I mRNA, but absent in the plasmid expressed N-
terminal RIG-I.
Virus plaque assay
Plaque assays were set up in a laminar-ﬂow safety cabinet in a BSL-
4 laboratory on conﬂuent monolayers of Vero E6 cells. Virus dilutions
of 10−1 through 10−6 were adsorbed to the cells by plating 200 μl of a
diluted specimen in duplicate onto the monolayer and incubating it
for 1 h at 37 °C. The inoculumwas removed and the monolayers were
overlaid with a solution of 1% agarose (SeaKem ME; FMC), 2% fetal
bovine serum, 2 mM L-glutamine, 15 mM HEPES (pH 7.5), 1×minimal
essential medium without phenol red (GIBCO, Invitrogen, Life
Technologies), and 1×antibiotic–antimycotic (GIBCO, Invitrogen,
Life Technologies). The plates were then incubated for 7 to 8 days at
37 °C and then ﬁxed overnight with 3% formaldehyde per well. Virus
plaques were revealed by a 1-h incubation with a 1:1000 dilution of a
rabbit anti-ebolavirus antibody followed by a second 1-h incubation
with a 1:1500 dilution of a horseradish peroxidase-labeled goat anti-
rabbit secondary antibody (BioRad). After thorough rinsing with
deionized H2O, 500 μl of True-Blue (KPL) substrate was added, and
after 10 to 15 min, virus plaques were counted.
Immunoblot
Cells were washed with chilled PBS and then lysed in 100 μl of ice-
cold lysis buffer (50 mM Tris–Cl, pH 8.0, 150 mM NaCl, 10% v/v
glycerol, 1% v/v Triton X-100, 2 mM EDTA, 1 mM PMSF, 20 μM
leupeptin containing aprotinin 0.15 μg/ml) for 20 min at 4 °C. The
protein content of different samples was determined using a protein
assay reagent (BioRad, Inc., CA, USA). Equal quantities of solubilized
protein were resolved by 10% SDS-PAGE, blotted to nitrocellulosemembrane and probed with the indicated primary antibodies, anti-
VP35 and anti-β-actin (Sigma, St. Louis, MO, USA). Antibody signals
were detected by chemiluminescence using secondary antibodies
conjugated to horseradish peroxidase and an ECL detection kit
(Amersham Biosciences, Inc., NJ, USA).
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